Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CBE 301

Next Previous
Drug Profile

CBE 301

Alternative Names: CBE-301

Latest Information Update: 26 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cell BioEngines
  • Class Antineoplastics; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Multiple myeloma

Most Recent Events

  • 11 Jan 2024 CBE 301 is available for licensing as of 11 Jan 2024. https://cellbioengines.com/our-pipeline
  • 11 Jan 2024 Preclinical trials in Multiple myeloma in USA (Parenteral) (Cell BioEngines pipeline, January 2024)
  • 10 Jan 2024 BioEngines plans to file IND application for CBE 301 in Q2 of 2025 (Cell BioEngines pipeline, January 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top